As of 2025-11-13, the Intrinsic Value of Arcoma AB (ARCOMA.ST) is 12.70 SEK. This ARCOMA.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 7.50 SEK, the upside of Arcoma AB is 69.30%.
The range of the Intrinsic Value is 10.39 - 16.85 SEK
Based on its market price of 7.50 SEK and our intrinsic valuation, Arcoma AB (ARCOMA.ST) is undervalued by 69.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 10.39 - 16.85 | 12.70 | 69.3% |
| DCF (Growth 10y) | 12.56 - 20.41 | 15.38 | 105.0% |
| DCF (EBITDA 5y) | 10.13 - 25.43 | 17.23 | 129.7% |
| DCF (EBITDA 10y) | 11.74 - 26.90 | 18.40 | 145.4% |
| Fair Value | 1.52 - 1.52 | 1.52 | -79.73% |
| P/E | 7.01 - 21.95 | 14.19 | 89.2% |
| EV/EBITDA | 7.10 - 19.11 | 12.26 | 63.5% |
| EPV | 23.67 - 34.12 | 28.90 | 285.3% |
| DDM - Stable | 1.83 - 4.11 | 2.97 | -60.4% |
| DDM - Multi | 5.65 - 10.40 | 7.37 | -1.8% |
| Market Cap (mil) | 107.32 |
| Beta | 0.08 |
| Outstanding shares (mil) | 14.31 |
| Enterprise Value (mil) | 83.44 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.66% |
| Cost of Debt | 4.77% |
| WACC | 6.78% |